 "The price of diagnostic tests, especially in the private sector, has been pinching the pockets of consumers")
Despite rising Covid cases across the country and the focus on getting tested for the virus, analysts say it will be a good strategy to exit stocks of diagnostic chains as they are pricing in most positives – at least for now. Over the long-run, however, Dr Lal Pathlabs, Metropolis Healthcare and Thyrocare Technologies still offer room for growth.
“The focus has now shifted to vaccination amid the recent spike in cases. Though stocks of diagnostic chains offer long-term value given the potential, most counters are factoring in the near-term positives. Valuation-wise, too, they are fairly priced at the current
